Zheng Y, Chu Y, Shao Z
Institute of Hematology and Blood Diseases Hospital, CAMS, PUMC, Tianjin 300020.
Zhonghua Xue Ye Xue Za Zhi. 1999 Apr;20(4):175-7.
To explore more effective regimen for severe aplastic anemia (SAA).
A prospective, randomized clinical trial was conducted to determine whether the outcome of SAA patients treated with the combination of antilymphocyte globulin(ALG) and cyclosporine A(CsA) (intensive immunosuppressive therapy, IIST) was better than that with ALG alone (non-intensive immunosuppressive therapy, NIIST).
The response rate of IIST group(83.7%) was significantly higher than that of NIIST group(57.6%), with a lower risk of early mortality and a shorter time to red cell transfusion independence. Furthermore, the recovery of bone marrow BFU-E and CFU-GM of the responding patients was more complete in IIST group than in NIIST group.
The treatment outcome was better with IIST than with NIIST for SAA.
探索治疗重型再生障碍性贫血（SAA）更有效的方案。
进行一项前瞻性随机临床试验，以确定接受抗淋巴细胞球蛋白（ALG）联合环孢素A（CsA）治疗的SAA患者（强化免疫抑制治疗，IIST）的疗效是否优于单纯使用ALG治疗的患者（非强化免疫抑制治疗，NIIST）。
IIST组的缓解率（83.7%）显著高于NIIST组（57.6%），早期死亡率更低，红细胞输注独立时间更短。此外，IIST组缓解患者的骨髓爆式红系集落形成单位（BFU-E）和粒-巨噬细胞集落形成单位（CFU-GM）的恢复比NIIST组更完全。
对于SAA，IIST的治疗效果优于NIIST。
